Initial combination therapy with DPP-IV inhibitors more effectively reduced MAGE than stepwise add-on therapies ( p = 0.006 ) , although no differences in MAGE were found based on HbA1c values .
These findings indicate that DPP-IV inhibitors are promising alternatives for reducing GV in type 2 diabetes patients .
Glycemic variability ( GV ) has been an emerging target for preventing complications related to type 2 diabetes .
For reducing GV , DPP-IV inhibitors have shown effectiveness compared to other oral anti-hyperglycemic drugs ( OADs ) , but systematic evaluation has yet to be existed .
Effects of sitagliptin as initial therapy in newly diagnosed elderly type 2 diabetics: A randomized controlled study
The objective of this study was to investigate the characteristics of blood glycemic excursion , incretins and pancreatic hormone secretion in elderly people with newly diagnosed type 2 diabetes mellitus ( T2DM ) and to study the effects of sitagliptin on glycemic excursion in these subjects . A total of 129 newly diagnosed T2DM patients were enrolled in the study from March 2012 to August 2013 .  Clinical data , serum incretin , pancreatic hormone and continuous glucose monitoring data were collected . Among these subjects , elderly patients ( NEDM ) r and omly received metformin combined with sitagliptin phosphate or glimepiride for 24 weeks . The blood glucose , glycosylated hemoglobin A1c ( GHbA1c ) , serum incretins and pancreatic hormone levels were determined . During the oral glucose tolerance test ( OGTT ) , 30 min insulin and C-peptide levels , 120 min insulin levels and ratio of the increases of insulin and blood glucose levels after 30 min of sugar loading ( ∆Ins30/∆Glu30 ) were significantly lower in elderly patients than in middle-aged patients ( P<0.05 ) . In addition , the glucagon elevation at 30 min was higher and the glucagon-like peptide-1 ( GLP-1 ) at 30 min was lower in the elderly patients ( P<0.05 ) . Glucose excursion indices , including the st and ard deviation of the average blood glucose , intraday mean average glucose excursions ( MAGE ) , and mean of daily differences ( MODD ) , were significantly higher in the elderly patients ( P<0.05 ) . During the OGTT , insulin , C-peptide and ∆Ins30/∆Glu30 results at 30 min and GLP-1 levels at 120 min in NEDM subjects were significantly increased ( P<0.05 ) and glucagon levels at 30 min was significantly lower after sitagliptin treatment ( P<0.05 ) compared with glimepiride . Moreover , MAGE and MODD were significantly lower in the sitagliptin group after treatment compared to those in the glimepiride group ( P<0.05 ) . No severe hypoglycemia or cardiovascular diseases were observed . Strong blood glucose excursions occur in elderly patients with newly diagnosed T2DM . Sitagliptin phosphate combined with metformin effectively and safely improves glycemic excursion and carbohydrate metabolism in NEDM patients by promoting the first phase of insulin and incretin secretion and inhibiting glucagon secretion of
Initial combination therapy with DPP-IV inhibitors more effectively reduced MAGE than stepwise add-on therapies ( p = 0.006 ) , although no differences in MAGE were found based on HbA1c values .
These findings indicate that DPP-IV inhibitors are promising alternatives for reducing GV in type 2 diabetes patients .
Glycemic variability ( GV ) has been an emerging target for preventing complications related to type 2 diabetes .
For reducing GV , DPP-IV inhibitors have shown effectiveness compared to other oral anti-hyperglycemic drugs ( OADs ) , but systematic evaluation has yet to be existed .